Shook David 4
4 · Lyell Immunopharma, Inc. · Filed Jun 11, 2025
Insider Transaction Report
Form 4
Shook David
Chief Medical Officer
Transactions
- Award
Common Stock
2025-06-09+21,900→ 21,900 total - Award
Option (right to buy)
2025-06-09+43,750→ 43,750 totalExercise: $12.47Exp: 2035-06-08→ Common Stock (43,750 underlying)
Footnotes (2)
- [F1]Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan ("RSUs"). 25% of the total shares subject to the RSUs will vest on June 9, 2026, and an additional 1/16th of the total shares subject to the RSUs per quarter thereafter, subject to the reporting person providing service through the applicable vesting date.
- [F2]25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.